Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3084520 | 0.83 | GRM2 (0.34) | HDAC1HDAC2HDAC3 | |
| SCHEMBL17368539 | 0.75 | P2RX7 (0.41) | HDAC1HDAC2HDAC3PSMB5BACE1 | |
| SCHEMBL16387219 | 0.70 | HDAC2 (0.52) | HDAC1HDAC2HDAC3PTGS2 | |
| SCHEMBL3974352 | 0.69 | CSF1R (0.48) | HDAC1HDAC2HDAC3PSMB5 | |
| SCHEMBL12642458 | 0.69 | TP53 (0.37) | SNCA | |
| SCHEMBL3973060 | 0.68 | CSF1R (0.49) | HDAC1HDAC2HDAC3PSMB5 | |
| SCHEMBL23140036 | 0.68 | HDAC1 (0.42) | HDAC1HDAC2HDAC3PSMB5PTGS2 | |
| SCHEMBL3076851 | 0.68 | PSMB5 (0.51) | HDAC1HDAC2HDAC3PSMB5PTGS2 | |
| SCHEMBL4264297 | 0.68 | SNCA (0.44) | SNCA | |
| SCHEMBL3081145 | 0.68 | PSMB5 (0.56) | HDAC1HDAC2HDAC3PSMB5PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| EP-2016057-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258666-A1 | c-fms kinase inhibitors | FLT3, FES, FER | HDAC1 3806/4885HDAC2 3662/4885HDAC3 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.